Cargando…

Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy

Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID‐19 vaccination. Overall, 45 patients (median 72 years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Thi H. O., Lim, Chhay, Lasica, Masa, Whitechurch, Ashley, Tennakoon, Surekha, Saunders, Natalie R., Allen, Lilith F., Rowntree, Louise C., Chua, Brendon Y., Kedzierski, Lukasz, Tan, Hyon‐Xhi, Wheatley, Adam K., Kent, Stephen J., Karapanagiotidis, Theo, Nicholson, Suellen, Williamson, Deborah A., Slavin, Monica A., Tam, Constantine S., Kedzierska, Katherine, Teh, Benjamin W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928803/ https://www.ncbi.nlm.nih.gov/pubmed/36819189 http://dx.doi.org/10.1002/jha2.639

Ejemplares similares

Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab
por: Hall, Victoria G, et al.
Publicado: (2023)

Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells
por: Nguyen, Thi H.O., et al.
Publicado: (2023)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Correction: Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

An update on Covid-19 serology
por: Kinsella, Paul M., et al.
Publicado: (2022)

Mucosal vaccines for SARS-CoV-2: triumph of hope over experience
por: Pilapitiya, Devaki, et al.
Publicado: (2023)

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
por: Molica, Stefano, et al.
Publicado: (2023)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

SARS-CoV-2-specific T cell memory with common TCRαβ motifs is established in unvaccinated children who seroconvert after infection
por: Rowntree, Louise C., et al.
Publicado: (2022)

Simultaneous development of zanubrutinib in the USA and China
por: Li, Guanqiao, et al.
Publicado: (2020)

Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series
por: Zhang, Yan, et al.
Publicado: (2021)

Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia
por: Tam, Constantine, et al.
Publicado: (2023)

Cross-lineage protection by human antibodies binding the influenza B hemagglutinin
por: Liu, Yi, et al.
Publicado: (2019)

Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome
por: Wong, Jonathan, et al.
Publicado: (2018)

Zanubrutinib for mantle cell lymphoma, Waldenström’s macroglobulinaemia
Publicado: (2021)

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
por: Muñoz, Javier, et al.
Publicado: (2022)

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
por: Tam, Constantine S., et al.
Publicado: (2022)

Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
por: Deshpande, Anagha, et al.
Publicado: (2022)

Disseminated fungal infection in a patient receiving zanubrutinib
por: Walsh, Madalyn, et al.
Publicado: (2023)

A novel UHPLC‒MS/MS method for quantitative analysis of zanubrutinib in rat plasma: application to an in vivo interaction study between zanubrutinib and triazole antifungal
por: Tang, Peng-fei, et al.
Publicado: (2023)

Suboptimal SARS-CoV-2−specific CD8(+) T cell response associated with the prominent HLA-A*02:01 phenotype
por: Habel, Jennifer R., et al.
Publicado: (2020)

Inducible Bronchus-Associated Lymphoid Tissues (iBALT) Serve as Sites of B Cell Selection and Maturation Following Influenza Infection in Mice
por: Tan, Hyon-Xhi, et al.
Publicado: (2019)

Sequencing B cell receptors from ferrets (Mustela putorius furo)
por: Wong, Julius, et al.
Publicado: (2020)

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
por: Tam, Constantine S., et al.
Publicado: (2020)

Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib
por: Lynes, John, et al.
Publicado: (2022)

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)

Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
por: Alsuhebany, Nada, et al.
Publicado: (2023)

Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity
por: Zhang, Wuji, et al.
Publicado: (2021)

Interplay of infection and vaccination in long-term protection from COVID-19
por: Tan, Hyon-Xhi, et al.
Publicado: (2022)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses
por: Koutsakos, Marios, et al.
Publicado: (2023)

P1242: ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
por: Zhang, Y., et al.
Publicado: (2022)

High expression of CD38 and MHC class II on CD8(+) T cells during severe influenza disease reflects bystander activation and trogocytosis
por: Jia, Xiaoxiao, et al.
Publicado: (2021)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Immune imprinting and SARS-CoV-2 vaccine design
por: Wheatley, Adam K., et al.
Publicado: (2021)

Zanubrutinib-induced liver injury: a case report and literature review
por: Atallah, Edmond, et al.
Publicado: (2021)

P1120: THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA
por: Liu, A., et al.
Publicado: (2022)

Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation
por: Li, Wenqi, et al.
Publicado: (2023)

Zanubrutinib-induced aseptic meningitis: a case report and literature review
por: Yang, Jinjun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_loea19h3umrocniio2qql6eo29